Combined Immunodeficiency Due to CTPS1 Deficiency — Comprehensive Disease Report

Disease: Combined Immunodeficiency Due to CTPS1 Deficiency MONDO: MONDO:0014391 · OMIM: #615897 (Immunodeficiency 24) · Orphanet: ORPHA:319391 · Category: Mendelian (autosomal recessive) Causal gene: CTPS1 (HGNC:2519; NCBI Gene 1503; UniProt P17812), chromosome 1p34.2

Summary

Combined immunodeficiency due to CTPS1 deficiency is an ultra-rare autosomal-recessive inborn error of immunity (IEI) first defined in humans in 2014. It is caused by biallelic loss-of-function variants in CTPS1, the gene encoding cytidine-5′-triphosphate synthase 1 — the enzyme that catalyzes the final, rate-limiting step of de novo pyrimidine biosynthesis (the ATP-dependent amination of UTP to CTP). Nearly all reported patients are homozygous for a single recurrent founder splice/frameshift allele (rs145092287; c.1692-1G>C, p.Thr566AspfsTer26), which behaves as a hypomorph that reduces CTPS1 protein and enzymatic activity by 80–90% owing to protein instability rather than loss of intrinsic catalytic function (PMID: 24870241; PMID: 32161190).

The disease is a "metabolic" combined immunodeficiency: the core lesion is an inability of activated T and B lymphocytes to sustain the massive nucleotide demand of clonal proliferation. Resting T cells express little CTPS1, but the enzyme is rapidly upregulated after antigen-receptor engagement; when it is deficient, antigen-driven proliferation collapses while proximal and distal T-cell receptor (TCR) signaling remain largely intact. The immunologic footprint is distinctive — near-absent proliferation and IL-2 secretion after TCR stimulation, combined with selective depletion of proliferation-dependent lineages (mucosal-associated invariant T [MAIT] cells, invariant NKT [iNKT] cells, memory B cells, and NK cells). Clinically, patients present in early childhood with severe, chronic, recurrent herpesvirus infections — especially Epstein–Barr virus (EBV) — recurrent encapsulated-bacterial infections, occasional invasive fungal disease, and a strong predisposition to EBV-driven B-cell lymphoproliferation and lymphoma (PMID: 31402499; PMID: 35983265).

The proliferation defect is metabolically reversible: adding exogenous CTP or its salvageable nucleoside precursor cytidine, or re-expressing wild-type CTPS1, restores normal T-cell proliferation in vitro. Definitive cure is achieved by allogeneic hematopoietic stem cell transplantation (HSCT). The same biology that makes CTPS1 loss immunodeficient makes the enzyme an attractive, isoform-selective drug target: pharmacologic CTPS1 inhibitors (e.g., STP938) are in clinical trials for relapsed/refractory lymphomas, and genetic or chemical CTPS1 inactivation rescues fatal autoimmunity in mouse models — the therapeutic mirror image of the human disease (PMID: 38438357; PMID: 37226519; PMID: 34583994).

Key Findings

Finding 1 — CTPS1 deficiency is an autosomal-recessive combined immunodeficiency caused by loss-of-function CTPS1 variants that cripple lymphocyte proliferation

The founding study used exome sequencing to identify a homozygous loss-of-function variant in CTPS1 as the cause of a novel, life-threatening immunodeficiency. The defining functional abnormality is that antigen-activated T and B cells fail to proliferate, even though proximal and distal TCR signaling are only weakly affected — establishing the disorder as a proliferation-specific (rather than signaling) defect. The causal gene is CTPS1 (HGNC:2519) on chromosome 1p34.2, and the disease is catalogued as OMIM #615897. As stated in the landmark paper, "we report the identification of a loss-of-function homozygous mutation (rs145092287) in CTPS1 in humans that causes a novel and life-threatening immunodeficiency, characterized by an impaired capacity of activated T and B cells to proliferate in response to antigen receptor-mediated activation" (PMID: 24870241).

Finding 2 — Mechanism: CTPS1 is rate-limiting for de novo CTP synthesis and is rapidly upregulated on TCR activation to fuel clonal expansion

CTPS1 catalyzes the ATP-dependent amination of UTP to CTP, the final and rate-limiting step of de novo CTP/pyrimidine synthesis. Activated CTPS1-deficient cells have decreased CTP levels, and the proliferation defect is metabolic and reversible: normal proliferation is restored by re-expressing wild-type CTPS1 or by supplying exogenous CTP or its nucleoside precursor cytidine (via the salvage pathway). Critically, CTPS1 is expressed at low levels in resting T cells but rapidly induced after TCR activation — explaining why the defect is unmasked specifically during the proliferative burst of an adaptive response. The paper reports: "Activated CTPS1-deficient cells had decreased levels of CTP. Normal T-cell proliferation was restored in CTPS1-deficient cells by expressing wild-type CTPS1 or by addition of exogenous CTP or its nucleoside precursor, cytidine. CTPS1 expression was found to be low in resting T cells, but rapidly upregulated following TCR activation" (PMID: 24870241).

Finding 3 — Immunophenotype: selective loss of MAIT, iNKT, memory B, and NK cells with impaired T-cell proliferation and IL-2 secretion; the founder allele is a hypomorph

Immunophenotyping of a cohort of 7 patients (all homozygous for c.1692-1G>C, p.T566Dfs26X) showed absence or low numbers of MAIT cells, iNKT cells, memory B cells, and NK cells, while other lymphocyte subsets were normal. Proliferation and IL-2 secretion in response to TCR activation were markedly decreased in all patients, whereas other T-cell effector functions were preserved — a pattern that distinguishes this disease from classical SCID (where thymic output itself fails). The molecular basis is a hypomorphic allele: the mutant protein is unstable, giving an 80–90% reduction in protein expression and activity, but the residual protein is catalytically normal when expressed at wild-type levels. Two verbatim statements anchor this: "Immune phenotyping performed in 7 patients showed absence or low numbers of mucosal-associated T cells, invariant NKT cells, memory B cells, and NK cells, whereas other subsets were normal. Proliferation and IL-2 secretion by T cells in response to TCR activation were markedly decreased in all patients, while other T cell effector functions were preserved"; and "The CTPS1T566Dfs26X mutant protein was found to be hypomorphic, resulting in 80%-90% reduction of protein expression and CTPS activity in cells of patients" (PMID: 32161190).

Finding 4 — Clinical presentation: early-onset severe/chronic herpesvirus (especially EBV) infection, encapsulated-bacterial infection, and EBV-driven B-cell lymphoproliferation/lymphoma

CTPS1 deficiency presents in early childhood with severe, recurrent, chronic viral infections — particularly EBV and other herpesviruses (VZV, HSV, CMV) — plus recurrent encapsulated-bacterial infections and a marked predisposition to EBV-associated non-malignant and malignant B-cell lymphoproliferative disorders. CTPS1 is repeatedly listed among the IEIs in which defective antigen-driven T-cell expansion impairs elimination of proliferating EBV-infected B cells. A review of EBV-susceptibility genetics places it precisely: "the defective expansion of EBV-specific CD8 T cells results from mutations in genes involved in T-cell activation (such as RASGRP1, MAGT1, and ITK), DNA metabolism (CTPS1) or co-stimulatory pathways (CD70, CD27, and TNFSFR9)" (PMID: 31402499). The infectious spectrum also extends to invasive fungal disease: the first reported case presenting "with coccidioidomycosis" documents "the first case of cytidine nucleotide triphosphate synthetase 1 (CTPS1) deficiency, a combined immunodeficiency impairing lymphocyte proliferation, presenting with coccidioidomycosis" (PMID: 35983265).

Finding 5 — Genetics/epidemiology: ultra-rare recessive disorder driven by a recurrent founder splice variant

The disorder is inherited autosomal-recessively, and reported patients are largely homozygous for a single recurrent founder variant, rs145092287 (c.1692-1G>C, p.T566Dfs26X), whose sharing across unrelated families indicates a founder effect. The disease is ultra-rare (ORPHA:319391; OMIM #615897; MONDO:0014391), with only a few dozen genetically confirmed patients described worldwide since 2014, frequently from consanguineous unions. Consanguinity and parental carrier status are the principal genetic risk context; no environmental risk or protective factors beyond pathogen exposure are established. The founder allele is documented in the discovery paper — "we report the identification of a loss-of-function homozygous mutation (rs145092287) in CTPS1 in humans" (PMID: 24870241) — and its precise nomenclature is confirmed in the cohort study as "a unique homozygous frameshift splice mutation (c.1692-1G>C, p.T566Dfs26X)" (PMID: 32161190).

Finding 6 — Mouse models: Ctps1 is embryonic-lethal when deleted and is required by high-turnover tissues, activated lymphocytes, and memory T cells

Conditional/inducible mouse studies show that deletion of Ctps1 (but not its paralog Ctps2) is embryonic-lethal, and that high-proliferation/renewal tissues — intestinal epithelium, erythroid and thymic lineages, activated B and T lymphocytes, and memory T cells — strongly depend on CTPS1. Both CTPS1 and CTPS2 are required for TCR-driven T-cell proliferation. These models faithfully recapitulate the human proliferation-dependence of adaptive immunity. As reported: "deletion of Ctps1, but not Ctps2, is embryonic-lethal. Tissue and cells with high proliferation and renewal rates, such as intestinal epithelium, erythroid and thymic lineages, activated B and T lymphocytes, and memory T cells strongly rely on CTPS1 for their maintenance and growth. However, both CTPS1 and CTPS2 are required for T cell proliferation following TCR stimulation" (PMID: 38438357).

Finding 7 — Treatment: allogeneic HSCT is curative; CTPS1 inhibition is the therapeutic mirror image

Allogeneic HSCT has been used successfully as definitive, curative treatment by replacing the CTPS1-deficient hematopoietic compartment (PMID: 29884857). Conversely, pharmacologic CTPS1 inhibition is an emerging immunosuppressive/anticancer strategy that harnesses the disease mechanism deliberately. In mice, "Deletion of Ctps1 in T cells or treatment with a CTPS1 inhibitor rescued Foxp3-deficient mice from fatal systemic autoimmunity and reduced the severity of experimental autoimmune encephalomyelitis. These findings support that CTPS1 may represent a target for immune suppression" (PMID: 38438357). A clinical-stage selective inhibitor is documented: "de novo CTP synthesis pathway enzyme CTPS1 whose inhibitor (STP938) is already in clinical trials for relapsed/refractory lymphomas (NCT05463263)" (PMID: 37226519).

Finding 8 — CTPS1 is a structurally validated, isoform-selective drug target with a functional confirmatory assay

Cryo-EM structural studies establish the structural basis for isoform-specific (CTPS1 vs CTPS2) small-molecule inhibition (PMID: 34583994), and CTPS activity in patient lymphocytes can be quantified by LC-MS/MS measurement of CTP, providing a functional confirmatory diagnostic assay (PMID: 31524312). Together with the clinical-stage inhibitor STP938 (PMID: 37226519) and mouse rescue-of-autoimmunity data (PMID: 38438357), these establish CTPS1 as a validated, druggable, isoform-selective target — the reverse-translation counterpart of the deficiency.

Detailed Report by Template Section

1. Disease Information

CTPS1 deficiency is a combined (T- and B-cell) immunodeficiency in which activated lymphocytes cannot proliferate adequately because they cannot generate sufficient CTP for the DNA/RNA and phospholipid synthesis of clonal expansion.

Synonyms: CTP synthase 1 deficiency; CTP synthetase 1 deficiency; cytidine triphosphate synthase 1 deficiency; Immunodeficiency 24 (IMD24); combined immunodeficiency due to impaired CTP synthesis.

Nature of evidence: aggregated disease-level evidence from published patient case series and mechanistic studies (not routine EHR data). Pivotal cohorts are small individual-patient series (~8 patients in PMID: 24870241; 7 immunophenotyped patients in PMID: 32161190).

2. Etiology

• Primary cause (genetic): biallelic loss-of-function CTPS1 variants; almost all patients homozygous for the founder allele c.1692-1G>C (p.T566Dfs26X).
• Genetic risk factors: the causal variant itself; consanguinity/carrier parents create the recessive risk context. No GWAS/susceptibility loci (monogenic).
• Modifier gene (candidate): CTPS2 (paralog); residual CTPS2 activity plausibly contributes to survival and to the hypomorphic phenotype (inferred from mouse redundancy; PMID: 38438357).
• Environmental risk factors: none causal. Pathogen exposure (especially EBV) is the essential trigger that unmasks disease. Sex is not a risk factor (autosomal).
• Protective factors: intact salvage pathway (cytidine→CTP) and CTPS2 are compensatory (inferred; salvage rescues the cellular defect in vitro, PMID: 24870241).
• Gene–environment interaction: the CTPS1 lesion is clinically silent until a proliferation-demanding challenge occurs; EBV is paradigmatic because it drives B-cell proliferation and requires vigorous CD8⁺ T-cell expansion to control (PMID: 31402499).

3. Phenotypes

Onset is typically early childhood/infancy; severity severe; course chronic/recurrent with acute decompensations. Frequencies are qualitative given small cohorts.

Distinctively, naïve T-cell output/thymic function and proximal TCR signaling are largely preserved, separating this disease from classical SCID (PMID: 24870241; PMID: 32161190). Quality of life: no formal EQ-5D/SF-36/PROMIS data exist; qualitatively the untreated burden is high (recurrent hospitalization, malignancy risk, shortened survival), while successful HSCT can restore substantially normal function.

4. Genetic / Molecular Information

• Causal gene: CTPS1 (EC 6.3.4.2), ~591-aa cytosolic enzyme with a glutaminase (GATase) domain and a synthetase/ligase (amidoligase) domain.
• Principal variant: NM_001905.4:c.1692-1G>C, p.(Thr566AspfsTer26), rs145092287. Type: splice-acceptor → frameshift → premature stop. Classification: Pathogenic. Consequence: loss of function via protein instability (80–90% ↓ protein/activity), residual protein catalytically normal (PMID: 32161190).
• Allele frequency: very rare in gnomAD/dbSNP; no healthy homozygotes.
• Origin: germline, autosomal recessive (not somatic).
• Functional class: loss of function (hypomorphic); no GOF or dominant-negative.
• Modifier genes: CTPS2 (partial redundancy). Epigenetics: none disease-specific (CTPS1 is transcriptionally induced by TCR activation — a regulatory feature, not an epigenetic-disease mechanism). Chromosomal abnormalities: none.

5. Environmental Information

No causal toxic/lifestyle factors. Infectious agents central to clinical expression: EBV/HHV-4 (dominant), other herpesviruses (VZV, HSV, CMV, HHV-6), encapsulated bacteria, and fungi (Coccidioides; PMID: 35983265). These are triggers/opportunists, not the disease cause.

6. Mechanism / Pathophysiology

Ordered causal chain:

1. Biallelic CTPS1 LOF variant (c.1692-1G>C, p.T566Dfs26X) leads to a frameshifted, unstable protein.
2. Protein instability results in 80–90% reduced CTPS1 protein/activity (residual protein catalytically normal) (PMID: 32161190).
3. Reduced activity impairs the rate-limiting de novo step UTP→CTP, causing decreased CTP when demand is high (PMID: 24870241).
4. Antigen-receptor activation normally triggers rapid CTPS1 upregulation; in deficiency this surge fails, so CTP becomes limiting for DNA/RNA/phospholipid synthesis during clonal expansion (PMID: 24870241).
5. CTP limitation blocks proliferation of activated T and B cells and reduces IL-2, while proximal/distal signaling and non-proliferative effector functions are preserved (branch: signaling intact, proliferation lost) (PMID: 32161190).
6. The proliferation block preferentially depletes proliferation-dependent lineages — MAIT, iNKT, memory B, NK cells (PMID: 32161190) (inferred link).
7. Impaired clonal expansion results in failure to expand EBV-specific CD8⁺ T cells, leading to uncontrolled herpesvirus infection and failure to eliminate EBV-infected proliferating B cells → EBV-driven B-cell lymphoproliferation/lymphoma (PMID: 31402499).
8. Reversal branch: exogenous CTP/cytidine (salvage) or wild-type CTPS1 rescues proliferation in vitro, and HSCT cures in vivo; pharmacologic CTPS1 inhibition reproduces the block therapeutically (PMID: 24870241; PMID: 29884857; PMID: 38438357).

Detail by category: Pathway — de novo pyrimidine/CTP biosynthesis (KEGG map00240; Reactome nucleotide metabolism), downstream of TCR→PI3K/AKT/mTOR and MYC-driven metabolic reprogramming (MYC positively regulates CTPS1; PMID: 37226519). Cellular process — S-phase/DNA replication and lymphocyte clonal expansion (GO:0006241 CTP biosynthetic process; GO:0044210 de novo CTP biosynthesis; GO:0042098 T-cell proliferation; GO:0042100 B-cell proliferation; GO:0007049 cell cycle). Protein dysfunction — LOF via instability; CTPS tetramerizes/polymerizes into filaments ("cytoophidia"), and an isoform-specific inhibitor pocket has been resolved by cryo-EM (PMID: 34583994). Metabolic change — ↓ intracellular CTP (CHEBI:17677); substrate UTP (CHEBI:15713); precursor cytidine (CHEBI:17562); glutamine (CHEBI:28300). Biochemical assay — reduced CTPS activity by LC-MS/MS CTP quantification (PMID: 31524312). Cell types (CL): CD8⁺ T (CL:0000625), CD4⁺ T (CL:0000624), B/memory B (CL:0000236/CL:0000787), NK (CL:0000623), MAIT (CL:0000940), iNKT (CL:0000921).

7. Anatomical Structures Affected

• Organ/system: immune (hematolymphoid) system — bone marrow (UBERON:0002371), thymus (UBERON:0002370), spleen (UBERON:0002106), lymph nodes (UBERON:0000029). Secondary: lung (UBERON:0002048; recurrent pneumonia, mediastinal fungal disease), liver/spleen (EBV disease, HLH), gastrointestinal tract (UBERON:0000160), and any lymphoma site.
• Tissue/cell: lymphoid tissue and circulating activated/proliferating lymphocytes; mouse data implicate high-renewal intestinal epithelium and erythroid/thymic lineages (PMID: 38438357).
• Subcellular: cytosol (GO:0005829), with downstream demand in the nucleus (DNA replication) and at membranes (phospholipids); CTPS filaments (GO:0097268).
• Lateralization: systemic/generalized (not lateralized).

8. Temporal Development

Congenital defect with clinical onset usually in infancy/early childhood, subacute-to-chronic, unmasked by the first significant viral (often EBV) challenge. Course is chronic and relapsing, punctuated by acute potentially fatal episodes (severe herpesvirus infection, HLH, lymphoma); progressive toward life-threatening complications without cure; lifelong unless corrected by HSCT. No formal staging; no spontaneous remission of the underlying defect, but treatment-induced immune reconstitution follows successful HSCT. Critical window: early diagnosis and HSCT before refractory infection/malignancy; uncontrolled pre-transplant infection worsens outcome (PMID: 33462728).

9. Inheritance and Population

Autosomal recessive (OMIM #615897). Ultra-rare (Orphanet prevalence <1/1,000,000; only a few dozen confirmed cases worldwide since 2014). Penetrance for the immunologic defect is high/complete in biallelic LOF individuals, with variable clinical expressivity (onset, infection spectrum, lymphoma/HLH). Founder effect for c.1692-1G>C (rs145092287) across unrelated families (PMID: 24870241; PMID: 32161190); consanguinity frequently contributory. Carrier frequency not precisely established (rare in gnomAD); targeted single-variant carrier testing feasible in founder families. Sex ratio ~1:1; age distribution predominantly pediatric at presentation. No genetic anticipation (not repeat-expansion); germline mosaicism not reported.

10. Diagnostics

• Immunology/labs: immunophenotyping shows low/absent MAIT, iNKT, memory B, NK cells with otherwise near-normal subsets; lymphocyte proliferation assays show markedly reduced proliferation and IL-2 on TCR/anti-CD3 stimulation with preserved proximal signaling (PMID: 32161190); CTPS activity assay (LC-MS/MS CTP quantification) is a functional confirmatory biomarker (PMID: 31524312); EBV viral load typically high/persistent.
• Genetic testing (definitive): WES or targeted IEI/PIRD NGS panels including CTPS1 are first-line; single-gene/targeted testing for c.1692-1G>C for founder-associated families and cascade testing; WGS for atypical/splice cases. CMA, karyotype, FISH, mtDNA, and repeat-expansion testing are not applicable. CTPS1 is included on international IEI/PIRD panels (PMID: 38644452).
• Imaging/pathology: non-specific imaging for infection/lymphoproliferation; biopsy with EBER in situ hybridization/IHC for EBV⁺ B-cell disease; marrow for HLH.
• Differential diagnosis: other EBV-susceptibility/CID IEIs — CD27, CD70, RASGRP1, MAGT1 (XMEN), ITK, SH2D1A (XLP1), XIAP, PIK3CD/PIK3R1, CORO1A, STK4, and SCID (PMID: 26424649; PMID: 31402499; PMID: 36209991).
• Screening: standard TREC-based newborn SCID screening does not reliably detect CTPS1 deficiency (naïve T-cell output preserved); cascade carrier screening and prenatal/preimplantation testing apply when the variant is known.

11. Outcome / Prognosis

Without curative treatment, prognosis is poor with high risk of death from overwhelming viral infection, HLH, or lymphoma in childhood/adolescence; uncontrolled pre-transplant infection is associated with mortality (5 of 9 IEI children in a pre-HSCT VST series, including CTPS1 patients, died before transplant; PMID: 33462728). Allogeneic HSCT is curative and can restore normal immune function (PMID: 29884857). Prognostic factors: timing of diagnosis/HSCT, infection control at transplant, donor match; EBV load and lymphoproliferation portend worse outcome. No disease-specific validated QoL instruments reported; formal survival statistics not established given rarity.

12. Treatment

Algorithm: diagnose → control infections (antimicrobials ± VST) and manage lymphoproliferation → proceed to allogeneic HSCT as definitive cure. Pharmacogenomics: not applicable.

13. Prevention

• Primary: not preventable individually (monogenic); population-level via genetic counseling and carrier/cascade screening in at-risk (often consanguineous) families, with prenatal/PGT options when the familial variant is known.
• Secondary: early molecular diagnosis (IEI panels/WES) in children with severe EBV disease/CID; TREC screening does not reliably detect it, so clinical vigilance is essential.
• Tertiary: antimicrobial/antiviral prophylaxis, EBV monitoring, avoidance of live vaccines, prompt infection treatment, pre-emptive lymphoproliferation management, timely HSCT.
• Immunization: live vaccines contraindicated; inactivated vaccines with caveat of variable responses.
• Counseling: autosomal-recessive recurrence risk (25% for carrier couples); cascade relative testing.

14. Other Species / Natural Disease

CTPS1 is evolutionarily conserved. Mouse ortholog Ctps1 (Mus musculus, NCBI:txid10090); paralog CTPS2 conserved across species; CTP synthetase activity is ancient (yeast URA7/URA8, bacterial pyrG). No naturally occurring CTPS1-deficiency disease is described in companion animals or wildlife (no established OMIA phenotype); knowledge derives from humans and engineered models. Complete loss is expected to be lethal across species (consistent with mouse embryonic lethality), so a viable natural analog would require a hypomorphic allele. Not zoonotic (non-infectious genetic disorder).

15. Model Organisms

• Mouse (principal model; PMID: 38438357): conditional/inducible Ctps1 (and Ctps2) knockouts and lineage-specific (e.g., T-cell) deletions plus pharmacologic-inhibition models. Ctps1 (not Ctps2) deletion is embryonic-lethal; activated B/T lymphocytes and memory T cells strongly depend on CTPS1, recapitulating the human proliferation defect; T-cell Ctps1 deletion or CTPS1 inhibition rescues Foxp3-deficient mice from fatal autoimmunity and reduces EAE. Limitations: complete null is embryonic-lethal (cannot model constitutive postnatal whole-body loss); human disease is caused by a hypomorphic allele, so conditional/partial models are required; mice are not EBV hosts, so the EBV-specific human disease is not reproduced.
• Cellular/in vitro: patient primary lymphocytes; CRISPR CTPS1 knockout in T-cell leukemia/lymphoma lines abolishes proliferation and causes DNA damage (PMID: 32161190; PMID: 37226519); reconstitution and cytidine/CTP-rescue assays; recombinant enzyme for cryo-EM/inhibitor design (PMID: 34583994); engineered Ctps1/Ctps2-knockout CHO auxotroph lines as bioproduction tools (PMID: 35249214).
• Resources: MGI (Ctps1), IMPC/IMSR for engineered alleles.

Mechanistic Model / Interpretation

 CTPS1 LoF variant (c.1692-1G>C, p.T566Dfs26X)
    │  (protein instability)
    ▼
 80–90% ↓ CTPS1 protein & activity  ─────────►  residual protein catalytically NORMAL
    │                                     (defect = amount, not intrinsic function)
    ▼
 ↓ de novo CTP synthesis (UTP ─X─► CTP), rate-limiting
    │
   [TCR/BCR activation demands rapid CTPS1 upregulation — cannot occur]
    ▼
 CTP becomes LIMITING during clonal expansion
    │
     ┌──────┴───────────────────────────────┐
     ▼                                        ▼
 Proliferation & IL-2 BLOCKED        Proximal/distal signaling &
 in activated T & B cells            non-proliferative effectors PRESERVED
     │
     ├──► Selective depletion: MAIT, iNKT, memory B, NK cells
     │
     └──► Failure to expand EBV-specific CD8+ T cells
 │
 ▼
      Uncontrolled EBV/herpesviruses ──► EBV-driven B-cell
      + recurrent bacterial/fungal        lymphoproliferation / lymphoma
      infection
 │
 [Metabolic bypass: exogenous cytidine/CTP or WT CTPS1
  RESCUES proliferation in vitro → HSCT cures in vivo;
  CTPS1 inhibitors reproduce the block therapeutically]

The unifying concept is that CTPS1 is a proliferation gatekeeper for adaptive immunity: dispensable for resting-cell metabolism and lymphocyte signaling, but indispensable for the nucleotide-biosynthesis burst that clonal expansion requires. This explains the paradoxical phenotype — near-normal lymphocyte numbers and signaling, but functional collapse of antigen-driven immunity, with the sharpest clinical consequence against EBV, the pathogen whose control most depends on massive CD8⁺ T-cell expansion.

Evidence Base

All papers are mutually consistent; none challenges the core model. The clearest independent replications are the founder-allele identity and hypomorphic mechanism across PMID: 24870241 and PMID: 32161190, and the mouse-model corroboration of proliferation-dependence in PMID: 38438357.

Supported vs Refuted Hypotheses

Supported: (i) CTPS1 LOF causes a combined immunodeficiency via impaired de novo CTP synthesis and consequent failure of activated-lymphocyte proliferation (strong: human + in vitro + mouse). (ii) The defect is metabolically bypassable by cytidine/CTP salvage and curable by HSCT (strong). (iii) A single founder splice allele underlies most cases (strong). (iv) Mouse models recapitulate the proliferation-dependent phenotype and reveal CTPS1 as a druggable immunosuppressive target (strong).

Refuted / not supported: the defect is not a proximal TCR-signaling defect (signaling is largely intact) and not a classical thymic-output SCID (naïve T-cell production preserved). No evidence for gain-of-function or dominant-negative action, environmental causation, or chromosomal/epigenetic mechanisms.

Limitations and Knowledge Gaps

1. Small cohorts / limited allelic diversity. Nearly all human data derive from patients homozygous for a single founder allele; genotype–phenotype consequences of other, non-founder LOF variants are essentially untested.
2. Epidemiology. No reliable prevalence, incidence, carrier-frequency, or survival statistics; disease known only from case reports and small cohorts.
3. Quality-of-life / long-term outcome data are absent; no validated instruments applied.
4. CTPS2 as modifier/phenocopy remains unresolved (the reported CTPS2 VUS is unproven; PMID: 29176466).
5. Metabolic (cytidine) therapy is supported only by in vitro rescue; no clinical trial in patients.
6. Model-organism gap: murine null is embryonic-lethal and mice are not EBV hosts, so no model fully reproduces the human EBV-driven disease.
7. Epigenetics, environmental modifiers, pharmacogenomics are effectively not applicable/not studied for this Mendelian disorder.
8. No large-scale patient omics (transcriptomic/proteomic/metabolomic) datasets are published.

Proposed Follow-up Experiments / Actions

1. International genotype–phenotype registry for CTPS1 deficiency to capture non-founder alleles, natural history, HSCT outcomes, and lymphoma incidence.
2. Functionally characterize additional CTPS1 variants (stability, catalytic activity, CTP rescue) using the LC-MS/MS CTP assay (PMID: 31524312) and cryo-EM-informed structure–function analysis (PMID: 34583994).
3. Test cytidine/uridine-nucleoside supplementation as adjunctive/bridging therapy in patient cells and, if promising, compassionate-use, building on in vitro rescue (PMID: 24870241).
4. Optimize HSCT timing/conditioning and define pre-transplant EBV/lymphoma control (including improved VST protocols delivered before prolonged infection) (PMID: 29884857; PMID: 33462728).
5. Develop humanized/EBV-permissive models (EBV-challenged humanized mice with CTPS1-null lymphocytes) to model the EBV-specific disease and test gene-correction/gene-therapy approaches.
6. Resolve CTPS2 candidacy through segregation, functional assays, and cohort screening (PMID: 29176466).
7. Leverage the reverse-translation link: use CTPS1-inhibitor programs (STP938; PMID: 37226519) to refine understanding of on-target immunosuppression, informing drug-safety (drug-induced phenocopy of the deficiency) and precision-immunosuppression opportunities.

Ontology Term Quick-Reference

• Disease: MONDO:0014391; OMIM:615897; ORPHA:319391
• Gene/protein: HGNC:2519 (CTPS1); UniProt P17812; NCBI Gene 1503
• Chemicals (CHEBI): CTP CHEBI:17677; UTP CHEBI:15713; cytidine CHEBI:17562; L-glutamine CHEBI:28300; ATP CHEBI:30616
• Biological process (GO): GO:0006241 (CTP biosynthetic process); GO:0044210 (de novo CTP biosynthesis); GO:0042098 (T-cell proliferation); GO:0042100 (B-cell proliferation); GO:0007049 (cell cycle)
• Cellular component (GO): GO:0005829 (cytosol); GO:0097268 (cytoophidium/filament)
• Cell types (CL): CL:0000625 (CD8⁺ T); CL:0000624 (CD4⁺ T); CL:0000236 (B cell); CL:0000787 (memory B); CL:0000623 (NK); CL:0000940 (MAIT); CL:0000921 (iNKT)
• Anatomy (UBERON): UBERON:0002371 (bone marrow); UBERON:0002370 (thymus); UBERON:0002106 (spleen); UBERON:0000029 (lymph node); UBERON:0002048 (lung); UBERON:0000160 (intestine)
• Treatment (NCIT): C15431 (HSCT); C107137 (allogeneic HSCT); C1702 (rituximab); C578 (IVIG)

Report compiled from 8 confirmed findings and 22 reviewed papers over 5 investigation iterations. Evidence types span human clinical/cohort, model organism (mouse), in vitro/cellular, structural, and review literature. Key PMIDs cited inline.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0014391 (4 mentions) - the report calls it "MONDO"; MONDO calls it combined immunodeficiency due to CTPS1 deficiency
• HP:0002850 (1 mention) - the report calls it "Laboratory"; HP calls it Decreased circulating IgM concentration
• HP:0003261 (1 mention) - the report calls it "Clinical"; HP calls it Increased circulating IgA concentration
• HP:0002841 (1 mention) - the report calls it "Infectious sign"; HP calls it Recurrent fungal infections
• CL:0000625 (2 mentions) - the report calls it "CD8⁺ T"; CL calls it CD8-positive, alpha-beta T cell
• CL:0000624 (2 mentions) - the report calls it "CD4⁺ T"; CL calls it CD4-positive, alpha-beta T cell
• CL:0000921 (2 mentions) - the report calls it "iNKT"; CL calls it type I NK T cell

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• GO:0044210 (2 mentions) - the report calls it "de novo CTP biosynthesis"; GO calls it 'de novo' CTP biosynthetic process
• CL:0000787 (2 mentions) - the report calls it "memory B"; CL calls it memory B cell
• CL:0000623 (2 mentions) - the report calls it "NK"; CL calls it natural killer cell, and lists "NK cell" among its other names
• CL:0000940 (2 mentions) - the report calls it "MAIT"; CL calls it mucosal-associated invariant T cell, and lists "MAIT" among its other names
• GO:0005829 (2 mentions) - the report calls it "Subcellular: cytosol", "cytosol"; GO calls it cytosol**
• GO:0097268 (2 mentions) - the report calls it "cytoophidium/filament"; GO calls it cytoophidium

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• GO:0005829 - called "Subcellular:** cytosol", "cytosol"

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, OMIM.